Next Article in Journal
Human Bartonellosis: An Underappreciated Public Health Problem?
Next Article in Special Issue
Immunological Assays used to Support Efficacy of Zika Virus Vaccines
Previous Article in Journal
Antiviral Therapy for the Next Influenza Pandemic
Previous Article in Special Issue
Pre-Clinical Pregnancy Models for Evaluating Zika Vaccines
Open AccessReview

Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease

Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, GA 30030, USA
Trop. Med. Infect. Dis. 2019, 4(2), 68; https://doi.org/10.3390/tropicalmed4020068
Received: 1 March 2019 / Revised: 11 April 2019 / Accepted: 15 April 2019 / Published: 19 April 2019
(This article belongs to the Special Issue Developing Zika Vaccines: Status Update)
Zika virus is an emerging mosquito-borne flavivirus that recently caused a large epidemic in Latin America characterized by novel disease phenotypes, including Guillain-Barré syndrome, sexual transmission, and congenital anomalies, such as microcephaly. This epidemic, which was declared an international public health emergency by the World Health Organization, has highlighted shortcomings in our current understanding of, and preparation for, emerging infectious diseases in general, as well as challenges that are specific to Zika virus infection. Vaccine development for Zika virus has been a high priority of the public health response, and several candidates have shown promise in pre-clinical and early phase clinical trials. The optimal selection and implementation of imperfect serologic assays are among the crucial issues that must be addressed in order to advance Zika vaccine development. Here, I review key considerations for how best to incorporate into Zika vaccine trials the existing serologic tools, as well as those on the horizon. Beyond that, this discussion is relevant to other intervention strategies to combat Zika and likely other emerging infectious diseases. View Full-Text
Keywords: Zika; virus; vaccine; arbovirus; vector-borne disease; serology; diagnostics; cross-reactivity; clinical trial Zika; virus; vaccine; arbovirus; vector-borne disease; serology; diagnostics; cross-reactivity; clinical trial
MDPI and ACS Style

Collins, M.H. Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease. Trop. Med. Infect. Dis. 2019, 4, 68.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop